Incidence and risk factors for genitourinary infection in individuals with type 2 diabetes using SGLT2 inhibitors

Abstract

Aim: To assess the frequency and risk factors for genitourinary infections in people with type 2 diabetes who are using SGLT2 inhibitors. Study design: A retrospective study. Place and Duration: Jinnah Hospital Lahore from March 2021 to March 2022. Methodology: This study included 57 people with type 2 diabetes who were using SGLT2 inhibitors.The parameters linked to genitourinary infections were observed via the use of multiple logistic regression analyses. This study utilized patients' medical records for observation and analysis. At the beginning of SGLT2 inhibitor therapy, data on the patient's age, gender, height, weight, duration of diabetes, menopausal status, HbA1c, and creatinine levels were collected. Two independent teams of scientists looked through the results of the investigation before concluding the final hypothesis. Results: Genitourinary infection occurred at a rate of 2.37 percent in the first month and 21.78 percent in the second month of the therapy. Genitourinary infections are more likely in individuals with HbA1c values between 7.0 and 8.0% (OR=3.45, p=0.001), 8.0% to 9.0% (OR=8.56, p=0.0001), and 9.0% (OR=11.45, p=0.0001), as well as diabetes medications such as SUR (OR=4.13, p0.001) and insulin (OR=3.81, p0.001).